Clinical trial
Phase I/Ib Trial of Single Agent MBF-362 in Solid Tumors
NCT05940571 is registered in ClinicalTrials.gov with Medibiofarma S.L. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase I/Ib Trial of Single Agent MBF-362 in Solid Tumors
- Lead sponsor
- Medibiofarma S.L.
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- November 24, 2022
- Completion date
- January 16, 2025
- Enrollment
- 16 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
cancer